CLEVELAND, Ohio — A recent clinical trial led by the University of Cincinnati looked at whether people living with HIV were more likely to take a monthly injection or a daily pill as treatment. The ...

AUSTIN (KXAN) — Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the virus. This summer, the FDA approved Gilead’s lenacapavir, ...

The U.S. Food and Drug Administration (FDA) recently approved a groundbreaking new option for preventing HIV, the virus that causes AIDS. The injectable drug lenacapavir was approved in June and is ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new long-lasting prophylactic treatment for HIV-1 that is administered once every 6 months. Lenacapavir (Yeytuo, Gilead ...

Yeztugo, a twice-yearly shot, could be the catalyst for stopping a recent spike in new HIV diagnoses. It's now available in ...

Long-acting injectable antiretroviral therapy improves treatment outcomes in individuals with HIV type 1 (HIV 1) who face adherence challenges, thereby addressing a persistent barrier in routine ...

Long-acting injectable cabotegravir + rilpivirine significantly reduced the risk of regimen failure vs daily oral ART in patients with HIV and a history of adherence challenges. Treatment with ...

In recent years, the story around HIV has shifted dramatically. What was once viewed as a life sentence is now increasingly seen as a manageable condition. Medication is responsible for much of that ...

The first shipment of Lenacapavir, a long-acting injectable that prevents HIV with two shots a year, arrived in South Africa ...